Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 601–700 of 1,007
Davila, R. E., & Faigel, D. O. (2003) · Gastrointestinal Endoscopy · doi:10.1067/mge.2003.317 · Cited by 110
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Sharma, M. R., Stadler, W. M., & Ratain, M. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr218 · Cited by 94
Holtkamp, N., Okuducu, A. F., Mucha, J., Afanasieva, A., Hartmann, C. J., Atallah, I., Estévéz‐Schwarz, L., Mawrin, C., Friedrich, R. E., Mautner, V., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi273 · Cited by 93
Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma
Chugh, R. K., Dunn, R. L., Zalupski, M. M., Biermann, J. S., Sondak, V. K., Mace, J. R., Leu, K. M., Chandler, W. F., & Baker, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.170 · Cited by 95
Ramanathan, R. K., Egorin, M. J., Takimoto, C. H. M., Remick, S. C., Doroshow, J. H., LoRusso, P. M., Mulkerin, D. L., Grem, J. L., Hamilton, A. L., Murgo, A. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0304 · Cited by 93
Self-citationMechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
Rubin, B. P., & Duensing, A. U. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700466 · Cited by 93
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
Meng, D., & Carvajal, R. D. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0414-1 · Cited by 97
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Loriaux, M., Levine, R. L., Tyner, J. W., Fröhling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101394 · Cited by 103
Self-citationTargeting c-Kit mutations: basic science to novel therapies
Sattler, M., & Salgia, R. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.004 · Cited by 101
Fairweather, M., Balachandran, V. P., Li, G. Z., Bertagnolli, M. M., Antonescu, C. R., Tap, W. D., Singer, S., DeMatteo, R. P., & Raut, C. P. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002281 · Cited by 92
Self-citationFGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
Chen, J., Lee, B. H., Williams, I. R., Kutok, J. L., Mitsiades, C. S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R. O., Coburn, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208989 · Cited by 97
Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 104
Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes
Nebot, N., Crettol, S., D’Esposito, F., Tattam, B. N., Hibbs, D. E., & Murray, M. T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00946.x · Cited by 91
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity
Zhou, L., An, N., Haydon, R. C., Zhou, Q., Cheng, H., Peng, Y., Jiang, W., Luu, H. H., Vanichakarn, P., Szatkowski, J. P., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00013-2 · Cited by 103
Gastrointestinal stromal tumors (GISTs): a review
Steigen, S. E., & Eide, T. J. (2009) · Apmis · doi:10.1111/j.1600-0463.2008.00020.x · Cited by 97
Potosky, A. L., Malin, J. L., Kim, B., Chrischilles, E. A., Makgoeng, S. B., Howlader, N., & Weeks, J. C. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr152 · Cited by 91
Yoo, C., Ryu, M., Kang, B. W., Yoon, S., Ryoo, B., Chang, H.-M., Lee, J., Beck, M. Y., Kim, T. W., & Kang, Y. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5785 · Cited by 91
Eklund, K. K., & Joensuu, H. (2003) · Annals of Medicine · doi:10.1080/07853890310001339 · Cited by 91
Self-citationSchwaederle, M., Daniels, G. A., Piccioni, D. E., Fanta, P. T., Schwab, R. B., Shimabukuro, K. A., Parker, B. A., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1061 · Cited by 90
Multitarget drugs: the present and the future of cancer therapy
Petrelli, A., & Valabrega, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902781907 · Cited by 96
Molecular Imaging Applications in Nanomedicine
Li, K. C., Pandit, S. D., Guccione, S., & Bednarski, M. D. (2004) · Biomedical Microdevices · doi:10.1023/b:bmmd.0000031747.05317.81 · Cited by 90
Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy
Gowda, R., Jones, N. R., Banerjee, S., & Robertson, G. P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000184 · Cited by 95
The Role of IGF-1R in Pediatric Malignancies
Kim, S. Y., Toretsky, J. A., Scher, D., & Helman, L. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0189 · Cited by 92
Bouchet, S., Poulette, S., Titier, K., Moore, N. D., Lassalle, R., Abouelfath, A., Italiano, A., Chevreau, C., Bompas, E., Collard, O., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.029 · Cited by 90
Resistance to imatinib (Glivec): update on clinical mechanisms
Weisberg, E., & Griffin, J. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00062-1 · Cited by 91
Evolution and Future of Skull Base Surgery: The Paradigm of Skull Base Meningiomas
Maio, S. D., Ramanathan, D., García-López, R., Rocha, M. H., Guerrero, F. P., Ferreira, M. L., & Sekhar, L. N. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.09.004 · Cited by 89
Coens, C., van der Graaf, W. T. A., Blay, J., Chawla, S. P., Judson, I. R., Sanfilippo, R. G., Manson, S. C., Hodge, R. A., Marreaud, S. I., Prins, J. B., et al. (2015) · Cancer · doi:10.1002/cncr.29426 · Cited by 89
Imatinib-induced fatal acute liver failure
Ridruejo, E., Cacchione, R., Villamil, A. G., Marciano, S., Gadano, A. C., & Mandó, O. G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i48.6608 · Cited by 76
Lasota, J. P., Dobosz, A. J. V., Wasąg, B., Woźniak, A., Kraszewska, E., Michej, W., Ptaszyński, K., Rutkowski, P. L., Sarlomo‐Rikala, M., Steigen, S. E., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700628 · Cited by 89
Lopes, L. F., West, R. B., Bacchi, L. M., van de Rijn, M., & Bacchi, C. E. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181d27ec8 · Cited by 89
Maier, J., Lange, T., Kerle, I., Specht, K., Bruegel, M., Wickenhauser, C., Jost, P., Niederwieser, D., Peschel, C., Duyster, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0765 · Cited by 88
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
Yuza, Y., Glatt, K. A., Jiang, J., Greulich, H., Minami, Y., Woo, M. S., Shimamura, T., Shapiro, G. I., Lee, J. C., Ji, H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.5.4003 · Cited by 88
“The finding of a novel exon 19 deletion by selection in cell culture: (1) demonstrates that the wild‐type EGFR gene is clearly not transforming; (2) supports the determination that each growth factor‐independent Ba/F3 cell strain is indeed transformed by mutant EGFR; (3) suggests that multiple in‐frame deletion mutant…”
BackgroundPhase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor
Sawaki, A., Nishida, T., Doi, T., Yamada, Y., Komatsu, Y., Kanda, T., Kakeji, Y., Onozawa, Y., Yamasaki, M., & Ohtsu, A. (2011) · Cancer · doi:10.1002/cncr.26120 · Cited by 88
Scagliotti, G. V., Stahel, R. A., Rosell, R., Thatcher, N., & Soria, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.001 · Cited by 98
Extragastrointestinal Stromal Tumors Presenting as Vulvovaginal/Rectovaginal Septal Masses
Lam, M. M., Corless, C. L., Goldblum, J. R., Heinrich, M. C., Downs-Kelly, E. P., & Rubin, B. P. (2006) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000215291.22867.18 · Cited by 88
Self-citationLiu, Y., Tseng, M., Perdreau, S. A., Rossi, F., Antonescu, C., Besmer, P., Fletcher, J. A., Duensing, S., & Duensing, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3497 · Cited by 88
Self-citationSamlowski, W. E., Moon, J., Tuthill, R. J., Heinrich, M. C., Haas, N. B., Merl, S. A., DeConti, R. C., Thompson, J. A., Witter, M., Flaherty, L. E., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181b9cf04 · Cited by 94
Self-citationBoichuk, S., Parry, J. A., Makielski, K. R., Litovchick, L., Baron, J. L., Zewe, J. P., Woźniak, A., Mehalek, K. R., Korzeniewski, N., Seneviratne, D. S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0579 · Cited by 94
Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors
Yao, J. C., Zhang, J. X., Rashid, A., Yeung, S. J., Szklaruk, J., Hess, K. R., Xie, K., Ellis, L. M., Abbruzzese, J. L., & Ajani, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1618 · Cited by 88
Rutkowski, P. L., Bylina, E., Klimczak, A., Świtaj, T., Falkowski, S., Kroc, J., Lugowska, I. A., Brzeskwiniewicz, M., Melerowicz, W., Osuch, C., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-107 · Cited by 90
Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., et al. (2014) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.004 · Cited by 86
Effects of Imatinib on Normal Hematopoiesis and Immune Activation
Appel, S., Balabanov, S., Brümmendorf, T. H., & Brossart, P. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0069 · Cited by 92
Aono, Y., Kishi, M., Yokota, Y., Azuma, M., Kinoshita, K., Takezaki, A., Sato, S., Kawano, H., Kishi, J., Goto, H., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0455oc · Cited by 98
Liegl, B., Hornick, J. L., Antonescu, C. R., Corless, C. L., & Fletcher, C. D. �. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817ec2e6 · Cited by 86
Self-citationGeorge, S., Reichardt, P., Lechner, T., Li, S., Cohen, D. P., & Demetri, G. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds179 · Cited by 86
Self-citationGao, X., Zhang, J., Huang, Z., Zuo, T., Lu, Q., Wu, G., & Shen, Q. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b05119 · Cited by 85
Molecular imaging strategies for drug discovery and development
Gross, S., & Piwnica-Worms, D. R. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.028 · Cited by 95
Role of KIT and platelet-derived growth factor receptors as oncoproteins
Fletcher, J. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.034 · Cited by 86
Self-citationSignal Events: Cell Signal Transduction and Its Inhibition in Cancer
Rowinsky, E. K. (2003) · The Oncologist · doi:10.1634/theoncologist.8-suppl_3-5 · Cited by 107
Gastrointestinal stromal tumors: A multidisciplinary challenge
Sánchez‐Hidalgo, J. M., Durán, M., Molero-Payan, R. M., Rufián‐Peña, S., Arjona‐Sánchez, Á., Casado-Adam, Á., Cosano, A., & Briceño‐Delgado, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i18.1925 · Cited by 103
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
Oudijk, L., Gaal, J., Korpershoek, E., van Nederveen, F. H., Kelly, L., Schiavon, G., Verweij, J., Mathijssen, R. H. J., den Bakker, M. A., Oldenburg, R. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.186 · Cited by 90
Jardim, D. L. F., Wheler, J. J., Hess, K. R., Tsimberidou, A. M., Zinner, R., Jankú, F., Subbiah, V., Naing, A., Piha-Paul, S. A., Westin, S. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089388 · Cited by 91
Gounder, M. M., & Maki, R. G. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1526-3 · Cited by 86
Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review
Huillard, O., Bakalian, S., Lévy, C., Desjardins, L., Rouïc, L. L.-L., Pop, S., Sablin, M., & Tourneau, C. L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.10.016 · Cited by 88
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
Argenta, P. A., Thomas, S. G., Judson, P. L., Downs, L. S., Geller, M. A., Carson, L. F., Jonson, A. L., & Ghebre, R. G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.01.012 · Cited by 86
Huynh, H., Pressiat, C., Sauvageon, H., Madelaine, I., Maslanka, P., Lebbé, C., Thiéblemont, C., Goldwirt, L., & Mourah, S. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000357 · Cited by 89
Setyono-Han, B., Stürzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M., Magdolen, V., Schmitt, M., Klijn, J. G. M., & Foekens, J. A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0712 · Cited by 85
Wagner, A. J., Chugh, R. K., Rosen, L. S., Morgan, J. A., George, S., Gordon, M. S., Dunbar, J., Normant, E., Grayzel, D., & Demetri, G. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0953 · Cited by 85
Self-citationAdvances in antifibrotic therapy
Ghiassi–Nejad, Z., & Friedman, S. L. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.6.803 · Cited by 88
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
de Wit, D., Guchelaar, H., den Hartigh, J., Gelderblom, H. A. J., & van Erp, N. P. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.007 · Cited by 96
Knowling, M., Blackstein, M. E., Tozer, R. G., Bramwell, V. H. C., Dancey, J. E., Dore, N. L., Matthews, S. W., & Eisenhauer, E. A. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-6406-7 · Cited by 93
Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?
Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2038 · Cited by 84
Gastrointestinal stromal tumors: Differential diagnosis
Dow, N. S., Giblen, G., Sobin, L. H., & Miettinen, M. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.09.002 · Cited by 84
Paller, C. J., Bradbury, P. A., Ivy, S. P., Seymour, L., LoRusso, P. M., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0521 · Cited by 84
Bauer, S., George, S., von Mehren, M., & Heinrich, M. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672500 · Cited by 89
Self-citationUterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT
Rushing, R. S., Shajahan, S., Damodaran, C., Wilder, J. L., Pulliam, J. F., Lee, E. Y., Ueland, F. R., van Nagell, J. R., Ahmed, M. M., & Lele, S. M. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00442-6 · Cited by 83
Choy, E., MacConaill, L. E., Cote, G. M., Le, L. P., Shen, J. K., Nielsen, G. P., Iafrate, A. J., Garraway, L. A., Hornicek, F. J., & Duan, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101283 · Cited by 87
Verbeek, H. H. G., Alves, M. M., de Groot, J. B., Osinga, J., Plukker, J. T. M., Links, T. P., & Hofstra, R. M. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2381 · Cited by 84
Fridlyand, J., Simon, R. M., Walrath, J. C., Roach, N., Buller, R. E., Schenkein, D. P., Flaherty, K. T., Allen, J. D., Sigal, E. V., & Scher, H. I. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4101 · Cited by 89
Rutkowski, P. L., Dêbiec‐Rychter, M., Nowecki, Z., Michej, W., Symonides, M., Ptaszyński, K., & Ruka, W. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03774.x · Cited by 82
Pittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010) · Oncogene · doi:10.1038/onc.2010.494 · Cited by 96
Nishida, T., Shirao, K., Sawaki, A., Koseki, M., Okamura, T., Ohtsu, A., Sugiyama, T., Miyakawa, K., & Hirota, S. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0746-y · Cited by 82
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors
Simon, S., Grabellus, F., Ferrera, L., Galietta, L. J. V., Schwindenhammer, B., Mühlenberg, T., Taeger, G., Eilers, G., Treckmann, J. W., Breitenbuecher, F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3839 · Cited by 82
Self-citationPopulation-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain
Rubió‐Casadevall, J., Marcos‐Gragera, R., Ortiz, M., Miró, J., Vilardell, L., Gironès, J., Hernández‐Yagüe, X., Cazador, A. C., Bernadó, L., Izquierdo, Á., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.07.015 · Cited by 92
Integrating cancer genomic data into electronic health records
Warner, J. L., Jain, S. K., & Levy, M. A. (2016) · Genome Medicine · doi:10.1186/s13073-016-0371-3 · Cited by 88
Sleijfer, S., Wiemer, E. A. C., & Verweij, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1037 · Cited by 87
Multiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 85
Self-citationChong, C. R., Bahcall, M., Capelletti, M., Kosaka, T., Ercan, D., Sim, T., Sholl, L. M., Nishino, M., Johnson, B. E., Gray, N. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1601 · Cited by 83
The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor
Schaefer, I., DeMatteo, R. P., & Serrano, C. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351231 · Cited by 92
Proteomics and biomarkers in clinical trials for drug development
Lee, J., Han, J. J., Altwerger, G. H., & Kohn, E. C. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.04.023 · Cited by 87
Hsieh, M., Fang, Y., Chang, W.-C., Kuo, H.-P., Lin, S.-Y., Liu, H.-P., Liu, C.-L., Chen, H.-C., Ku, Y.-C., Chen, Y.-T., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.005 · Cited by 86
Landi, B., Blay, J., Bonvalot, S., Brasseur, M., Coindre, J., Emile, J., Hautefeuille, V., Honoré, C., Lartigau, E. F., Mantion, G., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.07.006 · Cited by 81
Joensuu, H., de Braud, F., Grignagni, G., Pas, T. M. D., Spitalieri, G., Coco, P., Spreafico, C., Boselli, S., Toffalorio, F., Bono, P., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.151 · Cited by 80
Self-citationMonitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
Contractor, K. B., & Aboagye, E. O. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057273 · Cited by 81
Appel, S., Rupf, A., Weck, M. M., Schoor, O., Brümmendorf, T. H., Weinschenk, T., Grünebach, F., & Brossart, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1713 · Cited by 79
Holdhoff, M., Kreuzer, K., Appelt, C., Scholz, R., Na, I., Hildebrandt, B., Riess, H. B., Jordan, A., Schmidt, C. A., Etten, R. A. V., et al. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.11.006 · Cited by 80
Westerdijk, K., Desar, I. M. E., Steeghs, N., van der Graaf, W. T. A., van Erp, N. P., & on behalf of the Dutch Pharmacology and Oncology Group (DPOG) (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14185 · Cited by 86
MLL-rearranged leukemias: insights from gene expression profiling
Armstrong, S. A., Golub, T. R., & Korsmeyer, S. J. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00196-3 · Cited by 79
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 88
Khakoo, A. Y., & Yeh, E. T. H. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1225 · Cited by 79
Namløs, H. M., Boye, K., Mishkin, S. J., Barøy, T., Lorenz, S., Bjerkehagen, B., Stratford, E. W., Munthe, E., Kudlow, B. A., Myklebost, O., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0174 · Cited by 85
Waller, C. F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_1 · Cited by 94
Tarn, C., Skorobogatko, Y. V., Taguchi, T., Eisenberg, B. L., von Mehren, M., & Godwin, A. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3906 · Cited by 83
Self-citationThe 2.7 Å Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain
Walter, M., Lucet, I. S., Patel, O., Broughton, S. E., Bamert, R. S., Williams, N. K., Fantino, E., Wilks, A. F., & Rossjohn, J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.01.036 · Cited by 81
Mason, E. F., & Hornick, J. L. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.86 · Cited by 81
Johnston, F. M., Kneuertz, P. J., Cameron, J. L., Sanford, D. E., Fisher, S. B., Turley, R. S., Groeschl, R. T., Hyder, O. N., Kooby, D. A., Blazer, D. G., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2551-8 · Cited by 81
Vitali, F., Cohen, L. D., Demartini, A., Amato, A. M., Eterno, V., Zambelli, A., & Bellazzi, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162407 · Cited by 90
New developments in multitargeted therapy for patients with solid tumours
Tourneau, C. L., Faivre, S. J., & Raymond, É. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.003 · Cited by 78
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.